Special Issue

In Silico and In Vitro Screening of Small Molecule Inhibitors

Message from the Guest Editors

This Special Issue aims to highlight the latest advances, challenges and applications of in silico tools and in vitro screening in the field of drug discovery of SMIs. We welcome the submission of research and review articles on advances in the drug discovery, design and development of biological target inhibitors against different disease models. Scientists from both academia and industry are invited to submit their manuscripts covering relevant topics, including the design and synthesis of novel chemical entities (NCEs), repurposing of approved drugs, cell-based or animal experiments and in silico computational approaches to elucidate future directions in drug discovery.

The main objective of this Special Issue is to provide a comprehensive overview of cutting-edge in silico and in vitro screening methodologies for the design and development of bioactive NCEs with therapeutic relevance across various disease contexts, with a specific focus on the elucidation of SMI-biological target interaction mechanisms by employing the synergistic strategy of combining computational with experimental approaches.

Guest Editors

Dr. Usama Ammar

School of Applied Sciences, Edinburgh Napier University, Sighthill Campus, 9 Sighthill Court, Edinburgh EH11 4BN, UK

Dr. Domiziana Masci

Department of Basic Biotechnological Sciences, Intensivological and Perioperative Clinics, Catholic University of the Sacred Heart, Largo Francesco Vito, 1, 00168 Rome, Italy

Deadline for manuscript submissions

closed (10 June 2025)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/202617

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

